Newsfeeds - Spark Newswire

1 minute read

Syndax Pharmaceuticals Q2 EPS $(0.44) Beats $(0.71) Estimate, Sales $379.00K Beat $220.00K Estimate

Today, 8:08 PM

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.71) by 38.03 percent. This is a 4.76 percent decrease over losses of $(0.42) per share

SNDX

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 8:08 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 8:08 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

4 minute read

44 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 8:08 PM

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.

ACXP

1 minute read

News

Return On Capital Employed Overview: Syndax Pharmaceuticals

By Benzinga Insights

Today, 8:08 PM

In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million. In Q4, Syndax Pharmaceuticals brought in $380.00 thousand in sales but lost $19.86 million in earnings.

SNDX

1 minute read

Uncategorized

Citigroup Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $24

By Benzinga Newsdesk

Today, 8:08 PM

Citigroup analyst Yigal Nochomovitz initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $24.

SNDX

2 minute read

Uncategorized

Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial

By Vandana Singh

Today, 8:08 PM

Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of…

SNDX

6 minute read

Uncategorized

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings

By Shanthi Rexaline

Today, 8:08 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)

ABBV

9 minute read

Uncategorized

Earnings Scheduled For May 11, 2021

By Benzinga Insights

Today, 8:08 PM

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.

ABST

6 minute read

Uncategorized

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

By Shanthi Rexaline

Today, 8:08 PM

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.

ABCL